Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Average (2019 - 2025)

Historic Equity Average for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$1.9 billion.

  • BridgeBio Pharma's Equity Average fell 6171.58% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 6171.58%. This contributed to the annual value of -$1.4 billion for FY2024, which is 864.53% down from last year.
  • BridgeBio Pharma's Equity Average amounted to -$1.9 billion in Q3 2025, which was down 6171.58% from -$1.7 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Equity Average ranged from a high of -$141.6 million in Q1 2021 and a low of -$1.9 billion during Q3 2025
  • Over the past 5 years, BridgeBio Pharma's median Equity Average value was -$1.2 billion (recorded in 2022), while the average stood at -$1.1 billion.
  • In the last 5 years, BridgeBio Pharma's Equity Average plummeted by 59860.22% in 2021 and then soared by 1732.58% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Equity Average (Quarter) stood at -$802.9 million in 2021, then tumbled by 47.67% to -$1.2 billion in 2022, then fell by 7.51% to -$1.3 billion in 2023, then decreased by 5.4% to -$1.3 billion in 2024, then tumbled by 38.48% to -$1.9 billion in 2025.
  • Its last three reported values are -$1.9 billion in Q3 2025, -$1.7 billion for Q2 2025, and -$1.6 billion during Q1 2025.